Introduction
============

Esophageal cancer (EC) is a complex disease characterized by progressive dysphagia and emaciation. Because of aging and unhealthy lifestyles (eg, low intake of fruit and vegetables, the rising prevalence of smoking and drinking), EC constitutes a burden worldwide. Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of EC in China.[@b1-ott-10-5525],[@b2-ott-10-5525] The potential risk factors driving the high incidence of ESCC are not well understood. It is thought that poor nutritional status, insufficient fruit/vegetables intake, smoking, and drinking beverages at very high temperatures may be involved in the development of ESCC, though these potential risk factors cannot explain the total etiology of ESCC. Nowadays, it is considered that genetic variants may influence the risk of ESCC.

PPARs comprise a group of nuclear transcription factors, which are classified into three subtypes: PPARα, PPARβ, and PPARγ.[@b3-ott-10-5525] PPARγ is also named PPARG. In humans, the *PPARG* gene is located on chromosome 3p25. PPARG interacts with the retinoid X receptor, constructs a dipolymer, and then regulates its target genes, which are involved in cellular differentiation and metabolism of carbohydrates and lipids.[@b4-ott-10-5525] Polymorphisms in the *PPARG* gene are assumed to influence the development of malignancies and metabolism-related diseases. Pro12Ala (rs1801282 C\>G) and His449His (rs3856806 C\>T) polymorphisms are the two most common single-nucleotide polymorphism (SNPs) in the *PPARG* gene. Recently, a case--control study was conducted to assess the relationship of *PPARG* rs3856806 C\>T with susceptibility to EC. The results indicated that *PPARG* rs3856806 C\>T might be associated with the risk of EC.[@b5-ott-10-5525] In addition, the association between *PPARG* rs1801282 C\>G polymorphism and EC risk was unknown.

*IGF2BP2* binds to the 5′UTR of IGF2 mRNA and affects its translation.[@b6-ott-10-5525] Barghash et al reported that *IGF2BP2* expression correlated with poor survival in patients with esophageal adenocarcinoma and ESCC.[@b7-ott-10-5525] Case--control studies have indicated that *IGF2BP2* rs4402960 G\>T might be associated with the risk of breast cancer[@b8-ott-10-5525] and colorectal cancer.[@b9-ott-10-5525] In addition, it has been reported that *IGF2BP2* rs1470579 A\>C was associated with the risk of type 2 diabetes.[@b10-ott-10-5525],[@b11-ott-10-5525] However, the association between *IGF2BP2* polymorphisms and EC risk was unclear.

The aim of this case--control study was to explore the potential relationship of genetic variations in *PPARG* and *IGF2BP2* with risk of ESCC in the eastern Chinese Han population. *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms were selected and genotyped by SNPscan genotyping assays in 507 patients with ESCC and 1,496 controls.

Materials and methods
=====================

Subjects
--------

A total of 507 patients pathologically confirmed for ESCC from the Affiliated People's Hospital of Jiangsu University and the Affiliated Union Hospital of Fujian Medical University (mean age 62.77±8.01 years) were recruited in our study. The noncancer controls consisted of 1,496 age-, sex-, and residence-matched healthy individuals (mean age 62.77 ±8.84 years) without any cancer history or autoimmune diseases. All participants were enrolled between August 2013 and December 2016. EDTA-anticoagulated peripheral blood was collected after written consent had been signed. A questionnaire was used to obtain participants' risk factors and demographic variables. A body-mass index (BMI) ≥24 kg/m^2^ was accepted as the criterion of obesity and overweight.[@b12-ott-10-5525],[@b13-ott-10-5525] This study was approved by the institutional review boards of Jiangsu University (Zhenjiang, China) and Fujian Medical University (Fuzhou, China).

DNA extraction and genotyping
-----------------------------

Genomic DNA was extracted from whole blood using a DNA kit (Promega, Madison, WI, USA). *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T genotypes were determined by double ligation and multiplex-fluorescence polymerase chain reaction (SNPscan; Genesky Biotechnologies, Shanghai, China).[@b14-ott-10-5525] For quality control, 80 samples (4%) were randomly selected from the 2,003 DNA samples and genotyped again by another technician. Genotypes of *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms were confirmed.

Statistical analysis
--------------------

Continuous variables (age, BMI, height, and weight) are expressed as means ± SD. Comparisons of these continuous variables between two groups were performed using Student's *t*-test. The *χ*^2^ test was used to compare categorical variables (*PPARG* and *IGF2BP2* genotypes, BMI, sex, age, and smoking status and alcohol use). We checked the deviations for Hardy--Weinberg equilibrium in normal controls with an Internet-based calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>).[@b15-ott-10-5525]--[@b21-ott-10-5525] Statistical significance was defined as *P*\<0.05 (two-tailed). The relationships of *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms with ESCC susceptibility were determined by crude odds ratios (ORs) and 95% CIs. Adjusted for BMI, age, sex, alcohol use, and smoking status, multivariate linear regression was used to assess the potential association further among these polymorphisms and susceptibility to ESCC. SAS 9.4 software for Windows (SAS Institute, Cary, NC, USA) was used to analyze the data. SHEsis software (<http://analysis.bio-x.cn/myanalysis.php>; Bio-X, Shanghai, China) was used online to construct the haplotypes.[@b22-ott-10-5525]--[@b24-ott-10-5525]

Results
=======

Baseline characteristics
------------------------

Characteristics of 507 ESCC cases and 1,496 controls included in this case--control study are presented in [Table 1](#t1-ott-10-5525){ref-type="table"}. ESCC cases and controls were well matched on age and sex, as shown by *χ*^2^ tests (*P*=0.994 and *P*=0.406, respectively). As shown in [Table 1](#t1-ott-10-5525){ref-type="table"}, significant differences were found on smoking status and alcohol use between cases and controls (*P*\<0.001). The primary information for *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T SNPs is shown in [Table 2](#t2-ott-10-5525){ref-type="table"}. For these four genotyped SNPs, the successful ratio was 99.45%--99.5% in all 2,003 DNA samples. The concordance rates of quality-control testing were 100%. Minor allele frequency of *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T SNPs in controls was close to the minor allele-frequency data for Chinese ([Table 2](#t2-ott-10-5525){ref-type="table"}). In controls, the genotype frequencies for *PPARG* rs1801282 C\>G and rs3856806 C\>T polymorphisms were in Hardy--Weinberg equilibrium ([Table 2](#t2-ott-10-5525){ref-type="table"}).

Association of *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms with ESCC risk
-------------------------------------------------------------------------------------------------------------------------------------

The genotypes of *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms are summarized in [Table 3](#t3-ott-10-5525){ref-type="table"}. In single-locus analyses, the genotype frequencies of *PPARG* rs3856806 C\>T were 54.56% (CC), 39.09% (CT), and 6.35% (TT) in ESCC patients and 59.7% (CC), 36.13% (CT), and 4.16% (TT) in controls. When the *PPARG* rs3856806 CC homozygote genotype was used as the reference group, the *PPARG* rs3856806 CT genotype was correlated with a significantly increased risk of ESCC (CT vs CC, adjusted OR 1.28, 95% CI=1.02--1.6; *P*=0.033). When the *PPARG* rs3856806 CC homozygote genotype was used as the reference group, the *PPARG* rs3856806 TT genotype was correlated with a borderline significantly increased risk of ESCC (TT vs CC, adjusted OR 1.55, 95% CI=0.96--2.50; *P*=0.074). In the recessive model, when the *PPARG* rs3856806 CC/CT genotypes were used as the reference group, the *PPARG* rs3856806 TT homozygote genotype was not associated with susceptibility for ESCC (adjusted OR 1.41, 95% CI=0.88--2.26; *P*=0.153). In the dominant model, *PPARG* rs3856806 CT/TT genotypes were associated with an increased risk of ESCC compared with the *PPARG* rs3856806 CC genotype (adjusted OR 1.31, 95% CI=1.06--1.63; *P*=0.014) ([Table 3](#t3-ott-10-5525){ref-type="table"}). Logistic regression analyses showed that *PPARG* rs1801282 C\>G and *IGF2BP2* rs1470579 A\>C, rs4402960 G\>T polymorphisms were not correlated with the susceptibility for ESCC ([Table 3](#t3-ott-10-5525){ref-type="table"}).

Association of *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms with ESCC risk in different stratification groups
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To determine the potential effects of *PPARG* rs1801282 C\>G genotypes on ESCC risk in different subgroups according to BMI, age, sex, and smoking and drinking status, we carried out stratified analyses ([Table 4](#t4-ott-10-5525){ref-type="table"}). In the never-smoking subgroup, after adjustment for sex, age, BMI, and alcohol use, we found that the *PPARG* rs1801282 C\>G polymorphism increased ESCC risk in two genetic models (CG vs CC, adjusted OR 1.54, 95% CI 1.01--2.35, *P*=0.047; CG/GG vs CC, adjusted OR 1.54, 95% CI 1.01--2.34, *P*=0.044 \[[Table 4](#t4-ott-10-5525){ref-type="table"}\]).

[Table 5](#t5-ott-10-5525){ref-type="table"} shows genotype frequencies of *PPARG* rs3856806 C\>T in different subgroups. Significantly increased susceptibility to ESCC associated with the *PPARG* rs3856806 C\>T polymorphism was found among several subgroups ([Table 5](#t5-ott-10-5525){ref-type="table"}). In the female subgroup after adjustment for BMI, age, and smoking and drinking status, the *PPARG* rs3856806 CT/TT genotypes were associated with increased ESCC risk compared with the *PPARG* rs3856806 CC genotype (CT/TT vs CC, adjusted OR 1.55, 95% CI 1.02--2.35; *P*=0.041 \[[Table 5](#t5-ott-10-5525){ref-type="table"}\]). In the never-smoking subgroup after adjustment for BMI, age, sex, and drinking status, we found that *PPARG* rs3856806 CT/TT genotypes increased ESCC risk compared with the *PPARG* rs3856806 CC genotype (CT/TT vs CC, adjusted OR 1.37, 95% CI 1.03--1.82; *P*=0.032 \[[Table 5](#t5-ott-10-5525){ref-type="table"}\]). In the drinking subgroup after adjustment for BMI, age, sex, and smoking status, significantly increased risk of ESCC associated with the *PPARG* rs3856806 C\>T polymorphism was also found (TT vs CC, adjusted OR 3.36, 95% CI 1.05--12.74, *P*=0.041; TT vs CT/CC, adjusted OR 3.58, 95% CI 1.04--12.29, *P*=0.043 \[[Table 5](#t5-ott-10-5525){ref-type="table"}\]). In the never-drinking subgroup after adjustment for BMI, age, sex, and smoking status, significantly increased risk of ESCC associated with the *PPARG* rs3856806 C\>T polymorphism was also found (CT vs CC, adjusted OR 1.37, 95% CI 1.06--1.77, *P*=0.015; CT/TT vs CC, adjusted OR 1.37, 95% CI 1.07--1.75, *P*=0.013 \[[Table 5](#t5-ott-10-5525){ref-type="table"}\]). In addition, there was no significant risk of ESCC correlated with the *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T polymorphisms evident among any subgroup (data not shown).

SNP haplotypes
--------------

Using the SHEsis software,[@b22-ott-10-5525] we constructed eight haplotypes ([Table 6](#t6-ott-10-5525){ref-type="table"}). There were significant differences in the CGCC haplotype of the order rs1470579 A\>C, rs4402960 G\>T, rs1801282 C\>G and rs3856806 C\>T polymorphism distribution among ESCC cases and the control subjects (OR 2.23, 95% CI=1.09--4.59; *P*=0.025 \[[Table 6](#t6-ott-10-5525){ref-type="table"}\]).

Discussion
==========

In this case--control study, we explored the associations between the *PPARG* rs1801282 C\>G and rs3856806 C\>T and *IGF2BP2* rs1470579 A\>C and rs4402960 G\>T SNPs and risk of ESCC in the eastern Chinese Han population. Multivariable logistic analysis suggested that *PPARG* rs3856806 C\>T might be associated with an increased risk of ESCC. In different stratified analyses, there were significant associations between this polymorphism and risk of ESCC in the female, never-smoking, drinking, and never-drinking subgroups. In addition, we also found that *PPARG* rs1801282 C\>G increased ESCC risk in the never-smoking subgroup. To the best of our knowledge, this is the first study to identify a potential association between *PPARG* rs1801282 C\>G and rs3856806 C\>T polymorphisms and increased risk of ESCC in Asians.

PPARG is a member of the nuclear hormone-receptor superfamily and may possess anti-inflammatory properties.[@b25-ott-10-5525] PPARG also plays an important role in cell proliferation/differentiation, which affects the development and progression of cancer.[@b26-ott-10-5525],[@b27-ott-10-5525] The *PPARG* rs1801282 C\>G polymorphism is located in the exon B region of the *PPARG* gene. Deeb et al reported that this SNP was associated with decreased transactivation activity and lower BMI and promoted insulin sensitivity.[@b28-ott-10-5525] A recent meta-analysis suggested that *PPARG* rs1801282 C\>G polymorphism is a candidate for susceptibility to Asians.[@b29-ott-10-5525] The association between *PPARG* rs1801282 C\>G and risk of ESCC has not been studied before. In this study, we found that the *PPARG* rs1801282 CG genotype was more frequent in ESCC patients in the never-smoking subgroup, which was in accordance with the results of the meta-analysis just mentioned. The function of the *PPARG* rs1801282 C\>G SNP remains to be investigated in ESCC patients.

There was a difference in genotype distribution of the *PPARG* rs3856806 C\>T polymorphism between ESCC patients and controls. The *PPARG* rs3856806 CT and TT/CT genotypes were more frequent in ESCC patients compared with healthy controls, suggesting that the *PPARG* rs3856806 TT/CT and CT genotypes might contribute to the development of ESCC. The *PPARG* rs3856806 C\>T polymorphism is located in the exon of the *PPARG* gene. It is difficult to illustrate the exact function of a synonymous SNP. It is proposed that *PPARG* rs3856806 C→T substitution may disrupt the splice site,[@b30-ott-10-5525] and then affect the expression of PPARG. A meta-analysis suggested that *PPARG* rs3856806 C\>T is marginally associated with cancer susceptibility,[@b31-ott-10-5525] and our results were similar.

In the present investigation, we constructed eight haplotypes to study inherited patterns. We found that the C~rs1470579~G~rs4402960~C~rs1801282~C~rs3856806~ haplotype was associated with susceptibility for ESCC. Comparing the CGCC with the AGCC haplotype in the order of rs1470579 A\>C, rs4402960 G\>T, rs1801282 C\>G, and rs3856806 C\>T polymorphisms, we found that A→C variation in the rs1470579 A\>C locus led to susceptibility of the haplotype to ESCC. Several case--control studies have reported that *IGF2BP2* rs1470579 A\>C was associated with type 2 diabetes mellitus.[@b11-ott-10-5525],[@b32-ott-10-5525]--[@b34-ott-10-5525] However, a potential association between *IGF2BP2* rs1470579 A\>C polymorphism and ESCC risk was not found in our case--control study. In the future, more case--control studies with large samples and detailed risk factors should be carried out to confirm or refute our findings.

There were some limitations in our study. Firstly, this case--control study was limited by the moderate sample size of ESCC patients, which might lead to suboptimal power to identify true associations in the stratified analyses. Secondly, the controls were recruited from two local hospitals, and might not represent the general Chinese population well; this possible bias should not be ignored. Thirdly, only some functional SNPs in the *PPARG* and *IGF2BP2* genes were selected. The relationship of *PPARG* and *IGF2BP2* variants was not fully explored. In the future, a fine-mapping study should be conducted. Fourthly, detailed information on metastasis and survival of ESCC was not available at the time of research, which restricted further analysis on the potential role of *PPARG* and *IGF2BP2* variants in ESCC progression and prognosis. Finally, for lack of some environmental risk factors, such as lifestyle and intake of fruit/vegetables, the interaction of gene variants with environmental risk factors was not considered.

Conclusion
==========

Our findings highlight that *PPARG* rs1801282 C\>G and rs3856806 C\>T polymorphisms are candidates for susceptibility to ESCC in the eastern Chinese Han population. A fine-mapping study is required to confirm these preliminary findings.
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###### 

Distribution of selected demographic variables and risk factors in ESCC cases and controls

                             Cases (n=507)   Controls (n=1,496)   *P*-value[a](#tfn1-ott-10-5525){ref-type="table-fn"}           
  -------------------------- --------------- -------------------- ------------------------------------------------------ ------- ---------
  Age (years), mean ± SD     62.77±8.01                           62.77±8.84                                                     0.994
  Age (years)                                                                                                                    0.225
   \<63                      271             53.45                753                                                    50.33   
   ≥63                       236             46.55                743                                                    49.67   
  Sex                                                                                                                            0.406
   Male                      377             74.36                1,084                                                  72.46   
   Female                    130             25.64                412                                                    27.54   
  Tobacco use                                                                                                                    \<0.001
   Never                     247             48.72                1,090                                                  72.86   
   Ever                      260             51.28                406                                                    27.14   
  Alcohol use                                                                                                                    \<0.001
   Never                     341             67.26                1,329                                                  88.84   
   Ever                      166             32.74                167                                                    11.16   
  Height (cm)                166±7.29                             166.1±7.08                                                     0.743
  Weight (kg)                61.54±9.83                           66.11±9.92                                                     \<0.001
  BMI (kg/m^2^), mean ± SD   22.27±2.90                           23.91±3.03                                                     \<0.001
  BMI (kg/m^2^)                                                                                                                  \<0.001
   \<24                      370                                  779                                                            
   ≥24                       137                                  717                                                            

**Note:**

Two-sided *χ*^2^ test and Student's *t*-test.

**Abbreviations:** ESCC, esophageal squamous-cell carcinoma; BMI, body-mass index.

###### 

Primary information for *PPARG* rs1801282 C\>G, rs3856806 C\>T, and *IGF2BP2* 1470579 A\>C, rs4402960 G\>T polymorphisms

  Genotyped SNPs             Chromosome   Chromosome position (NCBI build 38)   MAF for Chinese in database   MAF in our controls (n=1,496)   *P*-value for HWE test in our controls   Genotyping method   Genotyping value (%)
  -------------------------- ------------ ------------------------------------- ----------------------------- ------------------------------- ---------------------------------------- ------------------- ----------------------
  *PPARG* rs1801282 C\>G     3            12351626                              0.07                          0.05                            0.911                                    SNPscan             99.5
  *PPARG* rs3856806 C\>T     3            12434058                              0.25                          0.22                            0.083                                    SNPscan             99.5
  *IGF2BP2* rs1470579 A\>C   3            185811292                             0.27                          0.25                            0.002                                    SNPscan             99.5
  *IGF2BP2* rs4402960 G\>T   3            185793899                             0.26                          0.25                            0.002                                    SNPscan             99.45

**Abbreviations:** SNPs, single-nucleotide polymorphisms; MAF, minor allele frequency; HWE, Hardy--Weinberg equilibrium.

###### 

Logistic regression analyses of association between *PPARG* rs1801282 C\>G, rs3856806 C\>T and *IGF2BP2* 1470579 A\>C, rs4402960 G\>T polymorphisms and risk of ESCC

  Genotype                   ESCC cases (n=507)   Controls (n=1,496)   Crude OR (95% CI)   *P*-value   Adjusted OR[a](#tfn4-ott-10-5525){ref-type="table-fn"} (95% CI)   *P*-value                        
  -------------------------- -------------------- -------------------- ------------------- ----------- ----------------------------------------------------------------- ----------- -------------------- -------
  *PPARG* rs1801282 C\>G                                                                                                                                                                                  
   CC                        440                  87.3                 1,334               89.59       1                                                                                                  
   GC                        63                   12.5                 151                 10.14       1.26 (0.92--1.73)                                                 0.144       1.24 (0.88--1.73)    0.219
   GG                        1                    0.20                 4                   0.27        0.76 (0.08--6.79)                                                 0.804       1.08 (0.11--10.5)    0.950
   GC+GG                     64                   12.7                 155                 10.41       1.25 (0.92--1.71)                                                 0.156       1.23 (0.88--1.72)    0.217
   CC+GC                     503                  99.8                 1,485               99.73       1                                                                             1                    
   GG                        1                    0.20                 4                   0.27        0.74 (0.08--6.62)                                                 0.786       1.05 (0.11--10.26)   0.966
   G allele                  65                   6.45                 159                 5.34                                                                                                           
  *PPARG* rs3856806 C\>T                                                                                                                                                                                  
   CC                        275                  54.56                889                 59.7        1                                                                                                  
   CT                        197                  39.09                538                 36.13       1.18 (0.96--1.46)                                                 0.125       1.28 (1.02--1.6)     0.033
   TT                        32                   6.35                 62                  4.16        1.66 (1.06--2.6)                                                  0.026       1.55 (0.96--2.5)     0.074
   CT+TT                     229                  45.44                600                 40.30       1.23 (1.01--1.51)                                                 0.043       1.31 (1.06--1.63)    0.014
   CC+CT                     472                  93.65                1,427               95.84       1                                                                             1                    
   TT                        32                   6.35                 62                  4.16        1.56 (1.01--2.42)                                                 0.047       1.41 (0.88--2.26)    0.153
   T allele                  261                  25.89                662                 22.23                                                                                                          
  *IGF2BP2* 1470579 A\>C                                                                                                                                                                                  
   AA                        280                  55.56                855                 57.42       1                                                                             1                    
   AC                        194                  38.49                517                 34.72       1.14 (0.92--1.41)                                                 0.218       1.09 (0.87--1.37)    0.453
   CC                        30                   5.95                 117                 7.86        0.78 (0.51--1.19)                                                 0.252       0.78 (0.5--1.22)     0.282
   AC+CC                     224                  44.44                634                 42.58       1.08 (0.88--1.32)                                                 0.465       1.04 (0.83--1.29)    0.748
   AA+AC                     474                  94.05                1,372               92.14       1                                                                             1                    
   CC                        30                   5.95                 117                 7.86        0.74 (0.49--1.12)                                                 0.159       0.76 (0.49--1.17)    0.213
   C allele                  254                  25.20                751                 25.22                                                                                                          
  *IGF2BP2* rs4402960 G\>T                                                                                                                                                                                
   GG                        294                  58.45                872                 58.56       1                                                                             1                    
   GT                        179                  35.59                506                 33.98       1.04 (0.84--1.29)                                                 0.698       0.99 (0.78--1.24)    0.904
   TT                        30                   5.96                 111                 7.45        0.8 (0.52--1.22)                                                  0.295       0.83 (0.53--1.29)    0.402
   GT+TT                     209                  41.55                617                 41.44       1.01 (0.82--1.23)                                                 0.694       0.96 (0.77--1.2)     0.737
   GG+GT                     473                  94.04                1,378               92.55       1                                                                             1                    
   TT                        30                   5.96                 111                 7.45        0.79 (0.52--1.19)                                                 0.261       0.84 (0.54--1.29)    0.418
   T allele                  239                  23.76                728                 24.45                                                                                                          

**Note:**

Adjusted for age, sex, BMI, alcohol use, and smoking status.

**Abbreviations:** ESCC, esophageal squamous-cell carcinoma; BMI, body-mass index; OR, odds ratio.

###### 

Stratified analyses between *PPARG* rs1801282 C\>G polymorphism and ESCC risk by sex, age, BMI, smoking status, and alcohol consumption

                        *PPARG* rs1801282 C\>G (case/control)[a](#tfn6-ott-10-5525){ref-type="table-fn"}   Adjusted OR[b](#tfn7-ott-10-5525){ref-type="table-fn"} (95% CI); *P*-value                                                                                                           
  --------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----- --- ------------------------------ ------------------------------- ------------------------------ -------------------------------
  Sex                                                                                                                                                                                                                                                                                           
   Male                 328/963                                                                            47/112                                                                       0/3   1   1.21 (0.81--1.79); *P*=0.351   --                              1.18 (0.8--1.75); *P*=0.407    --
   Female               112/371                                                                            16/39                                                                        1/1   1   1.55 (0.81--2.99); *P*=0.188   3.96 (0.25--63.97); *P*=0.332   1.62 (0.86--3.08); *P*=0.138   3.77 (0.23--60.91); *P*=0.349
  Age, years                                                                                                                                                                                                                                                                                    
   \<63                 207/679                                                                            28/66                                                                        1/2   1   1.43 (0.85--2.41); *P*=0.179   1.78 (0.13--24.51); *P*=0.665   1.43 (0.86--2.39); *P*=0.172   1.71 (0.13--23.44); *P*=0.687
   ≥63                  233/655                                                                            35/85                                                                        0/2   1   1.14 (0.73--1.78); *P*=0.555   --                              1.14 (0.73--1.77); *P*=0.571   --
  Smoking status                                                                                                                                                                                                                                                                                
   Never                210/976                                                                            34/106                                                                       1/4   1   1.54 (1.01--2.35); *P*=0.047   1.34 (0.14--12.59); *P*=0.796   1.54 (1.01--2.34); *P*=0.044   1.28 (014--11.97); *P*=0.830
   Ever                 230/358                                                                            29/45                                                                        0/0   1   0.92 (0.54--1.57); *P*=0.757   --                              0.92 (0.54--1.56); *P*=0.746   --
  Alcohol consumption                                                                                                                                                                                                                                                                           
   Never                296/1,186                                                                          41/134                                                                       1/3   1   1.20 (0.82--1.76); *P*=0.348   1.82 (0.18--18.63); *P*=0.614   1.22 (0.84--1.78); *P*=0.305   1.78 (0.17--18.25); *P*=0.626
   Ever                 144/148                                                                            22/17                                                                        0/1   1   1.41 (0.67--3); *P*=0.369      --                              1.32 (0.63--2.77); *P*=0.457   --
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                                 
   \<24                 319/695                                                                            47/78                                                                        1/1   1   1.32 (0.87--1.99); *P*=0.193   2.3 (0.14--37.56); *P*=0.558    1.34 (0.89--2.02); *P*=0.165   2.23 (0.14--36.38); *P*=0.574
   ≥24                  121/639                                                                            16/73                                                                        0/3   1   1.13 (0.63--2.03); *P*=0.691   --                              1.09 (0.61--1.96); *P*=0.775   --

**Notes:**

For *PPARG* rs1801282 C\>G, genotyping was successful in 507 (99.41%) ESCC cases and 1,496 (99.53%) controls;

adjusted for multiple comparisons (age, sex, BMI, smoking status, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

**Abbreviations:** ESCC, esophageal squamous-cell carcinoma; BMI, body-mass index; OR, odds ratio.

###### 

Stratified analyses between *PPARG* rs3856806 C\>T polymorphism and ESCC risk by sex, age, BMI, smoking status, and alcohol consumption

                        *PPARG* rs3856806 C\>T (case/control)[a](#tfn9-ott-10-5525){ref-type="table-fn"}   Adjusted OR[b](#tfn10-ott-10-5525){ref-type="table-fn"} (95% CI); *P*-value                                                                                                             
  --------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------- --- ------------------------------ ------------------------------- ------------------------------ -------------------------------
  Sex                                                                                                                                                                                                                                                                                              
   Male                 206/632                                                                            144/403                                                                       25/43   1   1.22 (0.93--1.59); *P*=0.146   1.57 (0.89--2.77); *P*=0.116    1.26 (0.98--1.63); *P*=0.078   1.46 (0.84--2.54); *P*=0.185
   Female               69/257                                                                             53/135                                                                        7/19    1   1.53 (0.99--2.36); *P*=0.054   1.57 (0.61--4.03); *P*=0.351    1.55 (1.02--2.35); *P*=0.041   1.33 (0.53--3.37); *P*=0.543
  Age, years                                                                                                                                                                                                                                                                                       
   \<63                 131/457                                                                            89/259                                                                        16/31   1   1.35 (0.96--1.9); *P*=0.081    1.6 (0.78--3.28); *P*=0.199     1.37 (0.99--1.9); *P*=0.061    1.42 (0.7--2.87); *P*=0.331
   ≥63                  144/432                                                                            108/279                                                                       16/31   1   1.26 (0.93--1.72); *P*=0.136   1.53 (0.79--2.96); *P*=0.209    1.31 (0.98--1.77); *P*=0.073   1.4 (0.73--2.68); *P*=0.306
  Smoking status                                                                                                                                                                                                                                                                                   
   Never                129/645                                                                            103/396                                                                       13/45   1   1.35 (1.01--1.82); *P*=0.044   1.35 (0.7--2.6); *P*=0.37       1.37 (1.03--1.82); *P*=0.032   1.2 (0.63--2.29); *P*=0.578
   Ever                 146/244                                                                            94/142                                                                        19/17   1   1.21 (0.84--1.73); *P*=0.302   1.82 (0.86--3.84); *P*=0.117    1.27 (0.9--1.79); *P*=0.171    1.69 (0.81--3.52); *P*=0.162
  Alcohol consumption                                                                                                                                                                                                                                                                              
   Never                179/793                                                                            142/472                                                                       17/58   1   1.37 (1.06--1.77); *P*=0.015   1.24 (0.7--2.21); *P*=0.458     1.37 (1.07--1.75); *P*=0.013   1.10 (0.63--1.94); *P*=0.740
   Ever                 96/96                                                                              55/66                                                                         15/4    1   1.03 (0.62--1.72); *P*=0.901   3.66 (1.05--12.74); *P*=0.041   1.19 (0.73--1.94); *P*=0.48    3.58 (1.04--12.29); *P*=0.043
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                                    
   \<24                 207/469                                                                            135/268                                                                       25/37   1   1.23 (0.93--1.62); *P*=0.156   1.53 (0.86--2.72); *P*=0.146    1.27 (0.97--1.67); *P*=0.08    1.42 (0.81--2.51); *P*=0.222
   ≥24                  68/420                                                                             62/270                                                                        7/25    1   1.41 (0.96--2.07); *P*=0.080   1.66 (0.68--4.05); *P*=0.268    1.43 (0.98--2.07); *P*=0.063   1.43 (0.6--3.44); *P*=0.423

**Notes:**

For *PPARG* rs3856806 C\>T, genotyping was successful in 507 (99.41%) ESCC cases and 1,496 (99.53%) controls;

adjusted for multiple comparisons (age, sex, BMI, smoking status, and alcohol consumption \[besides stratified factors accordingly\]) in a logistic regression model.

**Abbreviations:** ESCC, esophageal squamous-cell carcinoma; BMI, body-mass index; OR, odds ratio.

###### 

Haplotype frequencies (%) in cases and controls and risk of ESCC

           Cases (n=1,006)   Controls (n=2,978)   Crude OR (95% CI)   *P*-value                       
  -------- ----------------- -------------------- ------------------- ----------- ------------------- -------
  AGCC     543               53.98                1,679               56.38       Reference           
  CTCC     174               17.30                565                 18.97       0.95 (0.78--1.16)   0.624
  AGCT     164               16.30                430                 14.44       1.18 (0.96--1.45)   0.113
  CTCT     45                4.47                 107                 3.59        1.3 (0.91--1.87)    0.153
  AGGT     36                3.68                 79                  2.65        1.41 (0.94--2.12)   0.096
  CTGT     13                1.29                 34                  1.14        1.18 (0.62--2.26)   0.611
  CGCC     13                1.29                 18                  0.60        2.23 (1.09--4.59)   0.025
  AGGC     9                 0.89                 30                  1.01        0.93 (0.44--1.97)   0.845
  Others   9                 0.89                 36                  1.21        0.77 (0.37--1.62)   0.492

**Note:** With order of rs1470579 A\>C, rs4402960 G\>T, rs1801282 C\>G and rs3856806 C\>T in gene position.

**Abbreviations:** ESCC, esophageal squamous-cell carcinoma; OR, odds ratio.

[^1]: These authors contributed equally to this work
